Treatment of Fusarium Infection of the Central Nervous System: A Review of Past Cases to Guide Therapy for the Ongoing 2023 Outbreak in the United States and Mexico.

Introduction

Fusarium species are filamentous fungi ubiquitous in the environment and rarely cause invasive infection [ 1 ]. However, in many countries of the world, fusariosis ranks as the third most prevalent mold infection after aspergillosis and mucormycosis [ 1 – 4 ]. Risk factors for disease include profound or prolonged neutropenia, hematologic malignancy or allogeneic stem cell transplants [ 1 , 5 ]. Fusariosis typically presents with fungal pneumonia, skin lesions and fungemia, while infections of the central nervous system (CNS) have been very rarely reported [ 6 , 7 ]. Disseminated fusariosis has a fatality rate of 50–70% in immunocompromised individuals [ 8 ].

Despite the relative infrequency of this disease manifestation, an outbreak of Fusarium meningitis is currently ongoing [ 9 ]. Patients receiving epidural anesthesia in two clinics in Matamoros, Mexico have been identified at risk for Fusarium meningitis, with 10 confirmed cases, 9 deaths and another 22 probable or suspected cases in Matamoros involving United States (U.S.) cases, as of July 21, 2023 [ 10 ], with additional cases involving persons residing in Mexico. An additional outbreak occurred in late 2022 and early 2023 in Durango, Mexico, involving individuals receiving spinal anesthesia, including obstetric patients, with at least 79 cases of meningitis and 35 deaths with Fusarium spp. identified in a relevant proportion of cases as the causative organism [ 11 ]. The relationship, if any, between these locations and any potential common source remains unclear. While U.S. and Mexican Health Authorities continue their investigations, it is of paramount importance to review past cases in an attempt to guide current treatment regimens and ascertain prognostic information using prior reports of CNS fusariosis. We therefore reviewed the published literature for cases of CNS fusariosis to analyze treatment and outcome data.

Methods

We reviewed the published literature describing cases of invasive fusariosis involving the CNS, focusing on demographic characteristics of cases such as age and biologic sex, risk factors of disease such as immunosuppression or malignancy, location of infection, antifungal treatment, and outcome.

We searched PubMed, Google Scholar, and Web of Science using the keywords “Fusarium”, “fusariosis”, “CNS”, “brain”, and “central nervous system “ to select relevant clinical studies and case reports published in English between Jan 1, 1963 and July 20, 2023. We also searched citation lists of all relevant publications for additional references and contacted authors, when available, for additional case information.

Information on individual cases, namely age, sex, underlying diseases, extent of fusariosis, causative pathogen, treatment and outcomes was abstracted from the literature where available. Descriptive analysis was performed.

Results

Our literature review revealed 27 cases of CNS infections caused by Fusarium spp . , although one case report was unevaluable as it lacked any clinical data [ 12 ]. Thus, this case review included 26 cases in total (Table 1 ). Table 1 Prior reports of Central Nervous System (CNS) or Meningeal Fusariosis #/Ref./Year published Age Sex Risk Factors Causative Species Extent of Disease Treatment Outcome (day of death/follow up) 1[ 31 ] / 2022 70 NA Relapsed AML receiving induction therapy Fusarium spp. Maxillary sinus with intraorbital extension and meningitis L-AMB 8 mg/kg + VOR + intrathecal AMB NA 2[ 32 ] / 2022 32 F Prednisolone, methotrexate, adalimumab, rheumatoid arthritis F. proliferatum Brain mass with meningo-encephalitis IV VOR (12 mo) + surgery Alive (9 months follow-up) 3[ 33 ] / 2022 6 M Tuberculous meningitis F. falciforme Multiple brain abscesses and meningitis AMB 5 mg/kg + VOR + TERB + surgery Deceased (1 month) 4[ 34 ] / 2016 14 F Dexamethasone (4 mg, 3x/day for 14 days), Turberculous meningitis Fusarium spp. Meningitis AMB (14 days) Alive (25 days) 5[ 13 ] / 2015 50 F DM and ALL with failed auto-HSCT, ponatinib and dexamethasone F. solani Nasal septum ulcer, 1 cm brain mass VOR + ABLC 5 mg/kg + GCSF + surgery Hospice/Deceased (1 month) 6[ 35 ] / 2014 33 F None Fusarium spp. Brain mass VOR + TER + AMB + surgery Alive (18 months) 7[ 36 ] / 2008 53 F Promyelocytic leukemia F. oxysporum Brain abscess VOR Alive (5 months) 8[ 37 ] / 1998 NA NA ALL Fusarium spp. Brain abscess surgery Alive (NA) 9[ 38 ] / 1983 17 F Prednisone (60 mg/day) Fusarium spp. Brain abscess and meningitis AMB + intrathecal AMB + surgery (burrhole aspiration) Deceased (7 days) 10[ 39 ] / 1974 2 F 60% burn Fusarium spp. Brain, skin, kidney None (autopsy) Deceased (42 days) 11[ 40 ] / 1986 53 M Multiple myeloma F. oxysporum Skin, blood, brain AMB Deceased (30 days) 12[ 41 ] / 1991 15 M ALL Fusarium spp. Leptomeningitis AMB, 5FC, Miconazole + granulocyte transfusion Deceased (NA) 13[ 42 ] / 1996 6 F Aplastic anemia, allo BMT Fusarium spp. Skin, lung, brain AMB Deceased (NA) 14[ 43 ] / 2003 76 M AML F. solani Brain abscess ABLC 5 mg/kg then L-AMB 7.5 mg/kg, then VOR Deceased but negative for Fusarium at autopsy (30 weeks) 15[ 44 ] / 2009 55 F Lung transplant Fusarium spp. Brain abscess None (autopsy) Deceased (less than 7 days; not specified in report) 16[ 45 ] / 2007 NA NA NA F. solani Meningitis AMB Deceased (NA) 17[ 46 ] /2013 23 M FSGS Fusarium spp. Brain and detection in blood and urine None (autopsy) Deceased (NA) 18[ 47 ] / 1997 41 M AML, allo SCT, GVHD Fusarium spp. Brain, lung, skin ABLC Deceased (8 days) 19[ 47 ] / 1997 71 M AML Fusarium spp. Brain, sinuses, skin AMB Deceased (4 days) 20[ 47 ] / 1997 42 M CLL, allo SCT Fusarium spp. Brain, sinuses, lung, skin L-AMB Partial response / Deceased (85 days) 21[ 6 ] / 2003 7 F aplastic anemia, allo SCT Fusarium spp. Stroke, lung, skin AMB Deceased (5 days) 22[ 6 ] / 2003 42 F AML Fusarium spp. Cavernous thrombosis, lung, skin AMB Alive (NA) 23[ 6 ] / 2003 49 M Multiple Myeloma, allo SCT, GVHD F. solani Brain, lung, skin AMB, VOR Deceased (41 days) 24[ 6 ] / 2003 22 M AML, allo SCT, GVHD Fusarium spp. Brain, lung, skin AMB Deceased (11 days) 25 [ 48 ] / 2017 65 F DM and cirrhosis Fusarium spp. Brain abscesses, meningitis AMB then L-AMB Deceased (3 months) 26 [ 49 ] / 2015 NA NA Chronic granulomatous disease F. falciforme Epidural abscess, meningitis, cervical myelitis NA Deceased (NA) ABLC: amphotericin B lipid complex; ALL: acute lymphocytic leukemia; alloSCT: allogeneic stem cell transplant; AMB: amphotericin B; AML: acute myeloid leukemia; BMT: bone marrow transplant; CLL: chronic lymphocytic leukemia; DM: diabetes mellitus; FSGS: focal segmental glomerulosclerosis; GCSF: granulocyte colony stimulating factor; GVHD: graft versus host disease; HSCT: hematopoietic stem cell transplant; L-AMB: liposomal amphotericin B; NA: not available; TERB: terbinafine; VOR: voriconazole

Mean age of cases with CNS fusariosis was 36 years (range 2–76 years, data available from n = 22), and 12/22 (55%) of cases occurred in females, with the remaining 10/22 cases (45%) occurring in males (data not available in 4 cases). Risk factors (or absence of any risk factors) were reported in 25/26 cases and hematological malignancies/diseases were observed most commonly (15/25 cases, 60%), while another 4 cases received immunosuppressive treatment for other conditions. Of note, in only one case was it reported that patients had no known risk factor for disease (Table 1 ; Fig. 1 ). Fig. 1 Interchange between fusariosis in the environment and the healthcare setting, and the problem of antifungal resistance. Key Takeaways from this review on CNS fusariosis and treatment recommendation

Clinical manifestations varied widely, including meningitis, leptomeningitis, meningoencephalitis, brain abscesses and masses, cavernous thrombosis and stroke. Of note, 11/26 cases (42%) developed CNS fusariosis as part of their disseminated disease which almost always involved the lungs and skin, with positive blood cultures obtained in a relevant proportion of cases. Of those 11 with disseminated disease including CNS fusariosis, 9/11 (82%) had underlying hematological malignancy. Fusarium solani species complex was the causative pathogen in the majority of cases with species identification, while Fusarium oxysporum and Fusarium proliferatum were also detected. Fungal biomarkers and other diagnostics were rarely utilized; only in one single case report serum galactomannan and beta-D-glucan were tested, both giving negative results [ 13 ].

In terms of treatment, 13/21 cases (62%; in three cases CNS fusariosis was only diagnosed at autopsy, one additional case received surgery only and in one no data was available) received amphotericin B, with more recent cases mostly receiving lipid formulations of amphotericin B. Also 10/21 cases occurred before voriconazole was approved for clinical use. In some cases intrathecal amphotericin B was added, or later stepdown to oral voriconazole performed. Five cases (24%) received combination therapy with a polyene plus voriconazole ± additional antifungal therapy (e.g. terbinafine), while two cases (10%) received voriconazole monotherapy (Table 1 ). Surgery was performed in a total of 6/22 (27%) of cases.

Overall 18/25 cases (72%) had a fatal outcome, while 7/25 (28%) survived (for one case no outcome data available). The survivors included patients without any known risk factors, and four patients with underlying hematological malignancy; three of the survivors received polyene monotherapy (one of them later stepping down to oral voriconazole), two received voriconazole monotherapy, while each one received antifungal combination therapy or surgery only. Information regarding neutrophil count recovery in the hematologic malignancy patients was not available.

Discussion

Invasive fusariosis, although rare, is one of the most common mold infections, typically affecting immunocompromised persons. While fusariosis is one of the most frequent invasive mold infections, cases involving the CNS have been rarely reported and have nearly exclusively occurred in patients with known risk factors prior to the recent Fusarium meningitis outbreak in Durango, Mexico, and the current ongoing outbreak involving Fusarium solani species complex among patients who underwent procedures involving epidural anesthesia at two clinics in the city of Matamoros, Tamaulipas, Mexico. F. solani has been detected in CSF in patients receiving follow-up care in both Mexico and the U.S. In addition, elevated levels of β-D-glucan have been detected in the CSF of at least 6 of these patients. In total, 212 residents in 25 U.S. states and jurisdictions who underwent epidural anesthesia at these two clinics are deemed to be at risk for Fusarium meningitis [ 14 ]. Thus, guidance on how best to diagnose and treat these infections is important.

While culture from CSF, CNS abscess formations or blood remains the diagnostic gold standard, fungal biomarker testing was reported in only 1/26 cases reviewed here. However, fungal biomarkers tested from serum and CSF, like galactomannan and β-D-glucan, can be positive in fusariosis [ 1 ] and aid in the diagnosis of this CNS invasive fungal infection that carries very high morbidity and mortality [ 15 ], as does panfungal PCR from CSF or tissue. Next generation sequencing from blood specimens, which has shown promise for other mold infections [ 16 ], may present an important diagnostic method in the future, allowing detection of the causative species.

We reviewed the literature on published cases of fusariosis involving the CNS, and identified a total of 26 cases published between 1974 and 2022. The majority of cases involved young patients with a mean age of 36 years. Fifty-five percent involved females and 60% had underlying hematologic malignancy, with another 16% on immunosuppressants. The majority of infections were caused by Fusarium solani species complex. Overall, 72% of patients died. While the majority received monotherapy with amphotericin B (also because a significant proportion of cases occurred before voriconazole was approved for clinical use), most of the newer cases received liposomal amphotericin B or voriconazole monotherapy, with some receiving combination therapy with amphotericin B plus voriconazole with or without adjuvant surgery.

Although the majority of patients involved in the current outbreak in Mexico and the U.S. likely lack many of the risk factors found in the published cases – particularly hematologic malignancy and immunosuppression – treatment and patient outcomes from the published cases reviewed here may be instructive. Among the survivors from the published cases, 3 received amphotericin B monotherapy, 2 voriconazole monotherapy, 1 combination therapy with amphotericin B plus voriconazole, and one surgery only. Treatment with voriconazole, lipid formulations of amphotericin B, or combination therapy with these two agents have been recently recommended as first line options [ 1 ]. While no MIC testing was performed in the vast majority of cases reviewed here, it is known that Fusarium spp. are intrinsically resistant to echinocandin therapy, and commonly have elevated MICs to both triazoles and polyenes [ 17 , 18 ]. Past reports, in vitro susceptibility and murine models of infection suggest that combination therapy with liposomal amphotericin B and voriconazole should be used as first-line therapy [ 19 ], with the rationale to extend the spectrum of antifungal activity against these highly resistant pathogens. Intrathecal therapy may be used as adjunctive therapy, however consultation with those highly experienced with this treatment are recommended when considered for use. Data is insufficient to inform species-specific antifungal treatment recommendations [ 1 ]; although its clinical implications remain unclear [ 2 ], MIC testing should therefore be performed and may also guide therapy and novel antifungals obtained through compassionate use programs may also be needed in refractory cases, based on availability [ 20 ]. Novel antifungal compounds that are currently in clinical development, namely fosmanogepix or olorofim, have good CNS penetration and could also provide future treatment options for this deadly disease caused by Fusarium spp. that often show very high MICs against most available antifungals in vitro. [ 21 – 23 ].

Innate drug resistance in Fusarium spp. likely evolved in the environment as a survival mechanism. The presence of efflux pumps in Fusarium spp. have been shown to protect against phytoalexins, which are low molecular weight antimicrobial compounds produced by plants as a response to biotic and abiotic stresses, and the triazole fungicide tebuconazole [ 24 , 25 ]. Thermotolerance in times of global warming may further contribute to increased virulence in some Fusarium spp., as shown for Fusarium graminearum species complex, a pathogen to wheat and other cereal crops which can result in yield losses up to 75%, particularly during warmer and humid years [ 26 ]. This increased virulence leading to increased threat of food supply may lead to increased usage of fungicides in agriculture, including not only azoles like tebuconazole, but because of increasing resistance also fungicides with new mode of action like iplufenoquin which shares its mode of action with a new antifungal olorofim [ 27 ], or the fungicide aminopyrifen, which shares its mode of action with fosmanogepix [ 28 ]. This broad use of fungicides with similar mechanisms of actions with the antifungals used to treat infections in humans may lead to a further increase in antifungal resistance in the future (Fig. 1 ).

The relative lack of fusariosis cases in immunocompetent hosts speaks to the opportunistic nature of this genus. However, the attack rate and accompanying morbidity and mortality of infection in those receiving spinal anesthesia as the source reminds us that virulence cannot be insinuated for all pathogens. Under the right circumstances, it is likely that most microbes have the potential for virulence under certain conditions [ 29 ]. For example, Exserohilum was not a known cause of human CNS infections until a fungal meningitis outbreak with this organism was described in 2013 [ 30 ].

Of note, the current fusariosis outbreak in Matamoros, Mexico involved medical tourism. The majority of those affected were from the U.S. and underwent procedures in Mexico that had shorter waiting times and were lower cost. The high cost of health care for many in the U.S. is undoubtedly linked to these two recent outbreaks, and individuals seeking low-cost health care abroad may continue to be at risk for poor outcomes in the future.

In conclusion, two recent outbreaks of fusariosis involving the CNS, including one that is ongoing in Matamoros, Mexico and the U.S., are related to receipt of epidural anesthesia in Mexico. It is unclear if these two outbreaks are related. Given the high morbidity and mortality associated with these cases of invasive fusariosis, it is important to understand which treatment regimens may be best to treat these infections. Current guidelines recommend first-line treatment with voriconazole monotherapy, lipid formulations of amphotericin B, or combination therapy with these two regimens [ 20 ]. This case series also found that the majority of survivors from fusariosis involving the CNS were treated with voriconazole or amphotericin B monotherapy, with an additional patient treated with combination therapy using these agents and another from surgery alone. The findings in this case series and current guidelines for the treatment of invasive fusariosis should be instructive in the treatment of these patients.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Shared First Author: Martin Hoenigl and Jeffrey D. Jenks.

Funding

Open access funding provided by Medical University of Graz. No other funding obtained for this review.

Declarations

Conflict of interest

MH received research funding from Gilead, Astellas, MSD, IMMY, Mundipharma, Scynexis, F2G and Pfizer – all outside of the submitted work. All authors declare no conflict of interest. JDJ received research funding from Astellas, F2G, and Pfizer – all outside of the submitted work. MN received consulting fees from Knight, Pfizer, Abbvie, Abbott, Janssen, MSD, Astellas, Pharmalab, GSK, Takeda, AstraZeneca and Zodiac – all outside of the submitted work. GRT received research and consulting fees from Astellas, Amplyx, Cidara, F2G, Mayne, Melinta, Mundipharma, Scynexis, and served on the DSMB for Pfizer – all outside of the submitted work.

References

1. Hoenigl M Salmanton-García J Walsh TJ Nucci M Neoh CF Jenks JD Lackner M Sprute R Al-Hatmi AMS Bassetti M Carlesse F Freiberger T Koehler P Lehrnbecher T Kumar A Prattes J Richardson M Revankar S Slavin MA Stemler J Spiess B Taj-Aldeen SJ Warris A Woo PCY Young JH Albus K Arenz D Arsic-Arsenijevic V Bouchara JP Chinniah TR Chowdhary A de Hoog GS Dimopoulos G Duarte RF Hamal P Meis JF Mfinanga S Queiroz-Telles F Patterson TF Rahav G Rogers TR Rotstein C Wahyuningsih R Seidel D Cornely OA Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiology Lancet Infect Dis 2021 10.1016/s1473-3099(20)30784-2 33606997

2. Nucci M Jenks J Thompson GR Hoenigl M Santos MCD Forghieri F Rico JC Bonuomo V López-Soria L Lass-Flörl C Candoni A Garcia-Vidal C Cattaneo C Buil J Rabagliati R Roiz MP Gudiol C Fracchiolla N Campos-Herrero MI Delia M Farina F Fortun J Nadali G Sastre E Colombo AL Pérez Nadales E Alastruey-Izquierdo A Pagano L Do high MICs predict the outcome in invasive fusariosis? J Antimicrob Chemother 2020 10.1093/jac/dkaa516 33326585

3. Nucci M Marr KA Vehreschild MJ de Souza CA Velasco E Cappellano P Carlesse F Queiroz-Telles F Sheppard DC Kindo A Cesaro S Hamerschlak N Solza C Heinz WJ Schaller M Atalla A Arikan-Akdagli S Bertz H Galvao CC Herbrecht R Hoenigl M Harter G Hermansen NE Josting A Pagano L Salles MJ Mossad SB Ogunc D Pasqualotto AC Araujo V Troke PF Lortholary O Cornely OA Anaissie E Improvement in the outcome of invasive fusariosis in the last decade Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2013 10.1111/1469-0691.12409 24118322

4. Jenks JD Reed SL Seidel D Koehler P Cornely OA Mehta SR Hoenigl M Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy Int J Antimicrob Agents 2018 52 706 712 10.1016/j.ijantimicag.2018.08.005 30099056 PMC6231988

5. Nucci M Shoham S Abdala E Hamerschlak N Rico JC Forghieri F Nouer SA Cappellano P Solza C Gonzaga Y Nadali G Nucci F Colombo AL Albuquerque AM Queiroz-Telles Filho F Lima CBL Arrais-Rodrigues C Rocha V Marty FM Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, Is there a role for secondary prophylaxis? Mycoses 2019 62 413 417 10.1111/myc.12901 30720902

6. Nucci M Anaissie EJ Queiroz-Telles F Martins CA Trabasso P Solza C Mangini C Simoes BP Colombo AL Vaz J Levy CE Costa S Moreira VA Oliveira JS Paraguay N Duboc G Voltarelli JC Maiolino A Pasquini R Souza CA Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection Cancer 2003 98 315 319 10.1002/cncr.11510 12872351

7. McCarthy M Rosengart A Schuetz AN Kontoyiannis DP Walsh TJ Mold infections of the central nervous system N Engl J Med 2014 371 150 160 10.1056/NEJMra1216008 25006721 PMC4840461

8. Hayashida MZ Seque CA Enokihara M Porro AM Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate An Bras Dermatol 2018 93 726 729 10.1590/abd1806-4841.20187476 30156626 PMC6106674

9. WHO. Disease Outbreak News; Outbreak of suspected fungal meningitis associated with surgical procedures performed under spinal anaesthesia – the United States of America and Mexico. 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON470 .

10. Centers for Disease Control and Prevention NCfEaZIDN, Division of Healthcare Quality Promotion (DHQP). Fungal meningitis outbreak associated with procedures performed under epidural anesthesia in Matamoros, Mexico. 2023. https://www.cdc.gov/hai/outbreaks/meningitis-epidural-anesthesia.html#anchor_1686761372360 .

11. Organization. PAHOWH. 2022. Meningitis of unknown origin. December 10, 2022, Washington, D.C.: PAHO/WHO; 2022.

12. de Medeiros BC de Medeiros CR Werner B Neto JZ Loddo G Pasquini R Bleggi-Torres LF Central nervous system infections following bone marrow transplantation: an autopsy report of 27 cases J Hematother Stem Cell Res 2000 9 535 540 10.1089/152581600419215 10982253

13. Garcia RR Min Z Narasimhan S Bhanot N Fusarium brain abscess: case report and literature review Mycoses 2015 58 22 26 10.1111/myc.12271 25476184

14. Center of Disease Control and Prevention (CDC). Important updates on outbreak of fungal meningitis in U.S. patients Who underwent surgical procedures under epidural anesthesia in Matamoros, Mexico. https://emergency.cdc.gov/han/2023/han00492.asp .

15. Forster J Hoenigl M Suerbaum S Wagener J Dichtl K Serologic biomarkers in Candida and Aspergillus infections of the central nervous system: a comparison of galactomannan, mannan, and β-1,3-D-gucan testing from serum and cerebrospinal fluid Mycoses 2022 10.1111/myc.13451 35506957

16. Hoenigl M Egger M Price J Krause R Juergen Prattes P White L Metagenomic next-generation sequencing of plasma for diagnosis of COVID-19-associated pulmonary aspergillosis J Clin Microbiol 2023 10.1128/jcm.01859-22 36809121 PMC10035327

17. Katiyar SK Edlind TD Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae Antimicrob Agents Chemother 2009 53 1772 1778 10.1128/AAC.00020-09 19258277 PMC2681557

18. James JE Lamping E Santhanam J Cannon RD PDR transporter ABC1 is involved in the innate azole resistance of the human fungal pathogen Fusarium keratoplasticum Front Microbiol 2021 12 673206 10.3389/fmicb.2021.673206 34149660 PMC8211738

19. Ruíz-Cendoya M Mariné M Guarro J Combined therapy in treatment of murine infection by Fusarium solani J Antimicrob Chemother 2008 62 543 546 10.1093/jac/dkn215 18495651

20. Center for Disease Control and Prevention (CDC). Interim recommendations for diagnosing and managing suspected fungal meningitis associated with epidural anesthesia administered in Matamoros, Mexico. https://emergency.cdc.gov/coca/calls/2023/callinfo_060823.asp

21. Gebremariam T Gu Y Alkhazraji S Youssef E Shaw KJ Ibrahim AS The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections Antimicrob Agents Chemother 2022 66 e0038022 10.1128/aac.00380-22 35670592 PMC9295579

22. Hoenigl M Sprute R Egger M Arastehfar A Cornely OA Krause R Lass-Flörl C Prattes J Spec A Thompson GR 3rd Wiederhold N Jenks JD The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin Drugs 2021 10.1007/s40265-021-01611-0:1-27 34626339 PMC8501344

23. Wiederhold NP Najvar LK Jaramillo R Olivo M Birch M Law D Rex JH Catano G Patterson TF The orotomide olorofim is efficacious in an experimental model of central nervous system coccidioidomycosis Antimicrob Agents Chemother 2018 62 10 1128 10.1128/AAC.00999-18 PMC6125497 29941638

24. Hellin P King R Urban M Hammond-Kosack KE Legrève A The adaptation of Fusarium culmorum to DMI fungicides is mediated by major transcriptome modifications in response to azole fungicide, including the overexpression of a PDR transporter (FcABC1) Front Microbiol 2018 9 1385 10.3389/fmicb.2018.01385 29997598 PMC6028722

25. Abou Ammar G Tryono R Döll K Karlovsky P Deising HB Wirsel SG Identification of ABC transporter genes of Fusarium graminearum with roles in azole tolerance and/or virulence PLoS ONE 2013 8 e79042 10.1371/journal.pone.0079042 24244413 PMC3823976

26. Leplat JFH Abid M Steinberg C Survival of Fusarium graminearum , the causal agent of Fusarium head blight. A review Agron Sustain Dev 2013 33 1 97 111 10.1007/s13593-012-0098-5

27. Verweij PE Arendrup MC Alastruey-Izquierdo A Gold JAW Lockhart SR Chiller T White PL Dual use of antifungals in medicine and agriculture: How do we help prevent resistance developing in human pathogens? Drug Resist Updates 2022 65 100885 10.1016/j.drup.2022.100885 PMC10693676 36283187

28. Hatamoto M Aizawa R Kobayashi Y Fujimura M A novel fungicide aminopyrifen inhibits GWT-1 protein in glycosylphosphatidylinositol-anchor biosynthesis in Neurospora crassa Pestic Biochem Physiol 2019 156 1 8 10.1016/j.pestbp.2019.02.013 31027568

29. Pirofski LA Casadevall A Q and A: What is a pathogen? A question that begs the point BMC Biol 2012 10 6 10.1186/1741-7007-10-6 22293325 PMC3269390

30. Chiller TM Roy M Nguyen D Guh A Malani AN Latham R Peglow S Kerkering T Kaufman D McFadden J Collins J Kainer M Duwve J Trump D Blackmore C Tan C Cleveland AA MacCannell T Muehlenbachs A Zaki SR Brandt ME Jernigan JA Clinical findings for fungal infections caused by methylprednisolone injections N Engl J Med 2013 369 1610 1619 10.1056/NEJMoa1304879 24152260

31. Tawfiq RK Ranganath N Lehman V Yin LX Schuetz AN Breakthrough invasive Fusarium orbital rhinosinusitis with meningitis Mayo Clin Proc 2022 97 1953 1955 10.1016/j.mayocp.2022.06.026 36202502

32. Alavi Darazam I Sharifi G Jamali E Khodavaisy S Javandoust Gharehbagh F Hakamifard A Meningoencephalitis caused by Fusarium proliferatum : an unusual case Infection 2022 50 1023 1027 10.1007/s15010-022-01761-7 35112322

33. Karthigeyan M Singh K Kaur H Salunke P Pandey J Nallasamy K Multiple Fusarium brain abscesses in a young child Childs Nerv Syst 2022 38 1017 1021 10.1007/s00381-021-05320-7 34378119

34. Kaur R Panda P Fusarium co-infection in a patient of tubercular meningitis J Neuroanaesthesiol Crit Care 2016 03 03 249 251 10.4103/2348-0548.190076

35. Peterson A Pham MH Lee B Commins D Cadden J Giannotta SL Zada G Intracranial fusarium fungal abscess in an immunocompetent patient: case report and review of the literature J Neurol Surg Rep 2014 75 e241 e245 10.1055/s-0034-1387182 25485222 PMC4242827

36. Anten S Heddema ER Visser O Zweegman AS Images in haematology. Cerebral fungal abscess in a patient with acute promyelocytic leukaemia Br J Haematol 2008 140 253 10.1111/j.1365-2141.2007.06813.x 18028480

37. Antunes NL Hariharan S DeAngelis LM Brain abscesses in children with cancer Med Pediatr Oncol 1998 31 19 21 10.1002/(SICI)1096-911X(199807)31:1<19::AID-MPO4>3.0.CO;2-2 9607425

38. Steinberg GK Britt RH Enzmann DR Finlay JL Arvin AM Fusarium brain abscess Case report J Neurosurg 1983 58 598 601 6827355 10.3171/jns.1983.58.4.0598

39. Abramowsky CR Quinn D Bradford WD Conant NF Systemic infection by fusarium in a burned child. The emergence of a saprophytic strain J Pediatr 1974 84 561 564 10.1016/S0022-3476(74)80681-5 4834250

40. Anaissie E Kantarjian H Jones P Barlogie B Luna M Lopez-Berestein G Bodey GP Fusarium. A newly recognized fungal pathogen in immunosuppressed patients Cancer 1986 57 2141 2145 10.1002/1097-0142(19860601)57:11<2141::AID-CNCR2820571110>3.0.CO;2-N 3457624

41. Agamanolis DP Kalwinsky DK Krill CE Jr Dasu S Halasa B Galloway PG Fusarium meningoencephalitis in a child with acute leukemia Neuropediatrics 1991 22 110 112 10.1055/s-2008-1071428 1857495

42. Bleggi-Torres LF de Medeiros BC Neto JZ Loddo G Telles FQ de Medeiros CR Pasquini R Disseminated Fusarium sp. infection affecting the brain of a child after bone marrow transplantation Bone Marrow Transplant 1996 18 1013 1015 8932859

43. Vincent AL Cabrero JE Greene JN Sandin RL Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient Cancer Control 2003 10 414 419 10.1177/107327480301000511 14581897

44. Kleinschmidt-Demasters BK Disseminated Fusarium infection with brain abscesses in a lung transplant recipient Clin Neuropathol 2009 28 417 421 10.5414/NPP28417 19919815

45. Njambi S Huttova M Kovac M Freybergh PF Bauer F Muli JM Fungal neuroinfections: rare disease but unacceptably high mortality Neuro Endocrinol Lett 2007 28 Suppl 2 25 26 17558372

46. Muhammed M Anagnostou T Desalermos A Kourkoumpetis TK Carneiro HA Glavis-Bloom J Coleman JJ Mylonakis E Fusarium infection: report of 26 cases and review of 97 cases from the literature Medicine (Baltimore) 2013 92 305 316 10.1097/MD.0000000000000008 24145697 PMC4553992

47. Boutati EI Anaissie EJ Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management Blood 1997 90 999 1008 10.1182/blood.V90.3.999 9242529

48. Chen YJ Chou CL Lai KJ Lin YL Fusarium brain abscess in a patient with diabetes mellitus and liver cirrhosis Acta Neurol Taiwan 2017 26 3 128 132 29468621

49. Okura Y Kawamura N Okano M Toita N Takezaki S Yamada M Kobayashi I Ariga T Fusarium falciforme infection in a patient with chronic granulomatous disease: unique long-term course of epidural abscess Pediatr Int 2015 57 e4 e6 10.1111/ped.12458 25711271